Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab

被引：0
|
作者：
Park, W. [1 ]
Lopes, G. [1 ]
Kwon, D. [2 ]
Florou, V. [1 ]
Chae, Y. K. [3 ]
Warsch, J. [4 ]
Ishkanian, A. [5 ]
Jahanzeb, M. [6 ]
Mudad, R. [1 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA
[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA
[6] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Tumor mutation burden; biomarker; Nivolumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.07-025
引用
收藏
页码：S2004 / S2005
页数：2
相关论文
共 50 条
  • [1] Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer
    Sharpnack, Michael F.
    Cho, Ju Hwan
    Johnson, Travis S.
    Otterson, Gregory A.
    Shields, Peter G.
    Huang, Kun
    Carbone, David P.
    He, Kai
    LUNG CANCER, 2020, 146 : 36 - 41
  • [2] Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients
    Zhang, H.
    Deng, Y-M
    Chen, Z-C
    Tang, Y-C
    Yang, S.
    Zhang, S-D
    Liang, J-M
    Wang, Y-G
    Wu, X.
    Zhang, R-W
    Feng, W-N
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (14) : 7664 - 7672
  • [3] Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy
    Nie, Wei
    Xu, Mi-Die
    Gan, Lu
    Zhang, Yi
    Qian, Jie
    Gu, Kai
    Zhang, Xue-Yan
    Wang, Hui-Min
    Yan, Bo
    Gu, Ping
    Zhang, Bo
    Wang, Shu-Yuan
    Hu, Fang
    Li, Chang-Hui
    Zhong, Hua
    Han, Bao-Hui
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (06) : 189 - 195
  • [4] Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
    Cai, Liangliang
    Bai, Hua
    Duan, Jianchun
    Wang, Zhijie
    Gao, Shugeng
    Wang, Di
    Wang, Shuhang
    Jiang, Jun
    Han, Jiefei
    Tian, Yanhua
    Zhang, Xue
    Ye, Hao
    Li, Minghui
    Huang, Bingding
    He, Jie
    Wang, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer
    Xu, Dechen
    Li, Jie
    Wang, Dong
    Zhou, Li
    Jin, Jiahuan
    Wang, Yadong
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169
  • [6] Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer
    Wang, Xinan
    Ricciuti, Biagio
    Tom Nguyen
    Li, Xihao
    Rabin, Michael S.
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    CANCER RESEARCH, 2021, 81 (09) : 2566 - 2573
  • [7] Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab
    Park, W.
    Kwon, D.
    Saravia, D.
    Desai, A.
    Warsch, J.
    Vargas, F.
    El Dinali, M.
    Elias, R.
    Chae, Y.
    Kim, D. W.
    Warsch, S.
    Ishkanian, A.
    Ikpeazu, C.
    Mudad, R.
    Lopes, G.
    Jahanzeb, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2429 - S2430
  • [8] Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
    Xi Chen
    Liangjie Fang
    Yanping Zhu
    Zhang Bao
    Qing Wang
    Rong Liu
    Wenjia Sun
    Haiwei Du
    Jing Lin
    Bing Yu
    Songan Chen
    Jianya Zhou
    Jianying Zhou
    Cancer Immunology, Immunotherapy, 2021, 70 : 3513 - 3524
  • [9] Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
    Chen, Xi
    Fang, Liangjie
    Zhu, Yanping
    Bao, Zhang
    Wang, Qing
    Liu, Rong
    Sun, Wenjia
    Du, Haiwei
    Lin, Jing
    Yu, Bing
    Chen, Songan
    Zhou, Jianya
    Zhou, Jianying
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (12) : 3513 - 3524
  • [10] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Funazo, T.
    Yasuda, Y.
    Hirai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
12345